Who Supplies Rosuvastatin to India from PORTUGAL

To import finished pharmaceutical formulations containing Rosuvastatin into India, obtaining an import license from the Directorate General of Foreign Trade (DGFT) is mandatory. Additionally, the Central Drugs Standard Control Organization (CDSCO) requires registration of the product under Form CT-20/40/41. The Drug Controller General of India (DCGI) must approve the product, and a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare is necessary. The registration process typically takes 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. For Rosuvastatin formulations under HS Code 30049099, the application must include detailed product information, manufacturing details, and clinical data demonstrating safety and efficacy.

Imported Rosuvastatin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) Zone IV guidelines, is essential to ensure product stability under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify compliance with regulatory standards. Failure to meet quality standards may result in rejection of the batch and potential penalties.

In April 2025, the CDSCO mandated that all imported medicines, including finished formulations containing Rosuvastatin, must obtain import registration and licenses as per the Drugs and Cosmetics Act and associated rules. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Production-Linked Incentive (PLI) scheme, introduced in 2020, continues to impact the import of finished formulations by encouraging domestic manufacturing and reducing import dependency. Bilateral agreements between India and Portugal have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) standards enhancing the import process.

India imports finished Rosuvastatin formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, are often sourced from international markets. Despite a robust domestic pharmaceutical industry, certain specialized formulations are not produced locally, necessitating imports. The Indian market for Rosuvastatin formulations is substantial, with a total export value of $463.3 million across 427 exporters to 143 countries.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. A Social Welfare Surcharge (SWS) of 10% is also levied. Additional duties, such as Countervailing Duty (CVD), may apply depending on the product and country of origin. Exemptions and preferential rates may be available under specific trade agreements. The total landed duty for imports under HS Code 30049099 is approximately 23.536%.

India sources finished Rosuvastatin formulations from Portugal due to the availability of patented formulations and specialized dosage forms not produced domestically. Portugal's pharmaceutical industry is known for high-quality standards and compliance with international regulations. While other countries like China, Germany, and the United States also supply Rosuvastatin formulations, Portugal's competitive advantage lies in its adherence to stringent quality controls and the ability to provide specific formulations tailored to market needs. Portugal's share in India's Rosuvastatin import market is growing, reflecting its increasing competitiveness.

India imports finished Rosuvastatin formulations from Portugal due to the availability of patented formulations and specialized dosage forms not produced domestically. Portugal's pharmaceutical industry is known for high-quality standards and compliance with international regulations, making it a reliable source for these products.

Compared to other origins like China, Germany, and the United States, Portugal offers competitive advantages in terms of quality, regulatory compliance, and the ability to provide specific formulations tailored to market needs. While other countries may offer lower prices, Portugal's adherence to stringent quality controls and the provision of specialized formulations justify the higher cost.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product under Form CT-20/40/41.
3. 3Drug Import License: Secure a license from the Central Drugs Standard Control Organization.
4. 4No Objection Certificate (NOC): Obtain